{
  "description": "A drug treatment regimen for Colorectal cancer",
  "_filename": "example/PlanDefinition-ColoRectal.json",
  "package_name": "hl7.fhir.nz.cca",
  "date": "2020-06-29T20:14:18.417+12:00",
  "meta": {
    "profile": [ "http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition" ]
  },
  "publisher": "David Hay",
  "name": null,
  "_status": {
    "extension": [ {
      "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-additional-plan-status",
      "valueCode": "review"
    } ]
  },
  "useContext": [ {
    "code": {
      "code": "focus",
      "system": "http://terminology.hl7.org/CodeSystem/usage-context-type"
    },
    "valueCodeableConcept": {
      "coding": [ {
        "code": "781382000",
        "system": "http://snomed.info/sct",
        "display": "Colorectal cancer"
      } ]
    }
  } ],
  "type": "{:coding [{:system \\\"http://terminology.hl7.org/CodeSystem/plan-definition-type\\\", :code \\\"clinical-protocol\\\"}]}",
  "experimental": "false",
  "resourceType": "PlanDefinition",
  "title": "Colorectal Adjuvant FOLFOX (a7)",
  "package_version": "0.1.0",
  "extension": [ {
    "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
    "valueMarkdown": "Only for women"
  }, {
    "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer",
    "valueMarkdown": "Developed with the best of intentions."
  }, {
    "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-regimen-type",
    "valueCodeableConcept": {
      "text": "Folfox",
      "coding": [ {
        "code": "dummy",
        "system": "http://snomed.info/sct"
      } ]
    }
  }, {
    "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor",
    "extension": [ {
      "url": "factor",
      "valueCodeableConcept": {
        "coding": [ {
          "code": "TOUPDATE-SUPPORT4",
          "system": "http://snomed.info/sct",
          "display": "Diarrhoea risk"
        } ]
      }
    }, {
      "url": "value",
      "valueCodeableConcept": {
        "text": "low"
      }
    } ]
  }, {
    "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor",
    "extension": [ {
      "url": "factor",
      "valueCodeableConcept": {
        "coding": [ {
          "code": "TOUPDATE-SUPPORT8",
          "system": "http://snomed.info/sct",
          "display": "AntiFungal Prophylaxis"
        } ]
      }
    }, {
      "url": "value",
      "valueCodeableConcept": {
        "text": "low"
      }
    } ]
  }, {
    "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor",
    "extension": [ {
      "url": "factor",
      "valueCodeableConcept": {
        "coding": [ {
          "code": "TOUPDATE-SUPPORT2",
          "system": "http://snomed.info/sct",
          "display": "Hypersensitivity / Infusion related reaction ris"
        } ]
      }
    }, {
      "url": "value",
      "valueCodeableConcept": {
        "text": "low"
      }
    } ]
  } ],
  "contained": [ {
    "id": "ActTragacanth",
    "meta": {
      "profile": [ "http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition" ]
    },
    "text": {
      "div": "
Tragacanth administration, 3mg over 3 hours by continuous IV infusion
",
      "status": "additional"
    },
    "dosage": [ {
      "text": "3 mg over 3 hours by IV infusion",
      "route": {
        "coding": [ {
          "code": "180177004",
          "system": "http://snomed.info/sct",
          "display": "continuous intravenous infusion"
        } ]
      },
      "doseAndRate": [ {
        "doseQuantity": {
          "code": "mg",
          "value": 3,
          "system": "http://unitsofmeasure.org"
        },
        "rateQuantity": {
          "code": "h",
          "value": 3,
          "system": "http://unitsofmeasure.org"
        }
      } ]
    } ],
    "status": "draft",
    "resourceType": "ActivityDefinition",
    "productCodeableConcept": {
      "coding": [ {
        "code": "10711851000116105",
        "system": "https://nzulm.org.nz/nzmt",
        "display": "Tragacanth"
      } ]
    }
  } ],
  "status": "active",
  "id": "fcb1e4fd-ffb8-410a-b90b-8b604ed57243",
  "kind": null,
  "url": "http://hl7.org.nz/fhir/cca/PlanDefinition/ColoRectal",
  "action": [ {
    "title": "This is the only cycle in the regimen.",
    "action": [ {
      "extension": [ {
        "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
        "valueMarkdown": "Keep a close eye for side effects"
      }, {
        "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days",
        "extension": [ {
          "url": "day",
          "valueInteger": 1
        }, {
          "url": "instructions",
          "valueString": "Specific instructions for the day 1 administration"
        } ]
      }, {
        "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days",
        "extension": [ {
          "url": "day",
          "valueInteger": 4
        }, {
          "url": "instructions",
          "valueString": "Specific instructions for the day 4 administration"
        } ]
      } ],
      "description": "2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes",
      "definitionCanonical": "#act-cabergoline"
    }, {
      "extension": [ {
        "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days",
        "extension": [ {
          "url": "day",
          "valueInteger": 2
        }, {
          "url": "instructions",
          "valueString": "Specific instructions for the day 2 administration"
        } ]
      }, {
        "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days",
        "extension": [ {
          "url": "day",
          "valueInteger": 3
        }, {
          "url": "instructions",
          "valueString": "Specific instructions for the day 3 administration"
        } ]
      }, {
        "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days",
        "extension": [ {
          "url": "day",
          "valueInteger": 4
        }, {
          "url": "instructions",
          "valueString": "Specific instructions for the day 4 administration"
        } ]
      } ],
      "description": "3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours",
      "definitionCanonical": "#act-tragacanth"
    } ],
    "extension": [ {
      "url": "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
      "valueMarkdown": "Ensure not pregnant before starting"
    } ],
    "description": "Administration of Cabergoline and Tragacanth. Cycle length 14 days",
    "timingTiming": {
      "repeat": {
        "count": 1,
        "duration": 14,
        "durationUnit": "d"
      }
    },
    "selectionBehavior": "all"
  } ],
  "version": "0.1.0",
  "relatedArtifact": [ {
    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434",
    "type": "citation",
    "display": "test"
  }, {
    "url": "http://www.ncbi.nlm.nih.gov/pubmed/34324",
    "type": "citation",
    "display": "test2"
  } ],
  "contact": [ {
    "name": "David Hay",
    "telecom": [ {
      "value": "mailto:david.hay25@gmail.com",
      "system": "email"
    } ]
  } ]
}